A follow-up trial using the M87o vector to modify autologous CD34+ peripheral blood progenitor cells mobilized from HIV-1+ acquired immune deficiency syndrome (AIDS) patients with cancer had to be stopped after treatment of three patients due to the adverse events observed in the SCID and CGD trials described above (NCT00858793). This evidence concerns the gene CD34 and AIDS.